Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;43(6):1090-1098.
doi: 10.1007/s12664-023-01511-z. Epub 2024 Mar 9.

Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review

Rajath Ramegowda  1 , Pankaj Gupta  2
Affiliations
Review

Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review

Rajath Ramegowda et al. Indian J Gastroenterol. 2024 Dec.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common primary malignancies of the liver and a leading cause for cancer-related deaths worldwide. HCC surveillance aims at early detection. The recommended strategy for screening HCC is biannual ultrasound with or without alpha-fetoprotein. However, this strategy is associated with sub-optimal sensitivity. Abbreviated magnetic resonance imaging (AMRI) is a promising alternative to ultrasound (US) for surveillance of HCC. The data regarding the role of AMRI in HCC screening is evolving. There are different AMRI protocols, each having its merits and disadvantages. In this review, we discuss the need for AMRI, protocols of AMRI and hindrances to widespread adoption of AMRI.

Keywords: Biomarkers; Cancer screening; Diagnostic imaging; Early detection of cancer; Hepatocellular carcinoma; Imaging; Magnetic resonance; Sensitivity; Specificity; Surveillance; Tumor; Ultrasound.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol. 2010;101:476–80. https://doi.org/10.1002/jso.21522 . - DOI - PubMed
    1. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48:571–7. https://doi.org/10.1016/j.dld.2016.02.005 . - DOI - PubMed
    1. Labeur TA, Runge JH, Klompenhouwer EG, Klümpen HJ, Takkenberg RB, van Delden OM. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. Abdom Radiol. 2019;44:2740–50. https://doi.org/10.1007/s00261-019-02030-2 . - DOI
    1. Tohra S, Duseja A, Taneja S, et al. Experience with changing etiology and nontransplant curative treatment modalities for hepatocellular carcinoma in a real-life setting—a retrospective descriptive analysis. J Clin Exp Hepatol. 2021;11:682–90. https://doi.org/10.1016/j.jceh.2021.02.002 . - DOI - PubMed - PMC
    1. Shetty VV, Kellarai A. Comprehensive review of hepatocellular carcinoma in India: current challenges and future directions. JCO Glob Oncol. 2022;8:e2200118. https://doi.org/10.1200/GO.22.00118 . - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources